Atrazine (ATZ) is one of the most commonly used herbicides in the United States. Previous studies have hypothesized the role of ATZ as an endocrine disruptor (EDC), and developmental exposure to ATZ has been shown to lead to behavioral and morphological alterations. Specific epigenetic mechanisms responsible for these alterations, however, are yet to be elucidated. In this study, we exposed zebrafish embryos to 0.3, 3, and 30 ppb (µg/L) of ATZ for 72 hours post fertilization. We performed whole-genome bisulfite sequencing (WGBS) to assess the effects of developmental ATZ exposure on DNA methylation in female fish brains. The number of differentially methylated genes (DMG) increase with increasing dose of treatments. DMGs are enriched in neurological pathways with extensive methylation changes consistently observed in neuroendocrine and reproductive pathways. To assess the effects of DNA methylation on gene expression, we integrated our data with transcriptomic data. Four genes, namely CHD9, FRAS1, PID1, and PCLO, were differentially expressed and methylated in each dose. Overall, this study identifies specific genes and pathways with aberrant methylation and expression following ATZ exposure as targets to elucidate the molecular mechanisms of ATZ toxicity and presents ATZ-induced site-specific DNA methylation as a potential mechanism driving aberrant gene expression.
INTRODUCTION
Atrazine (6-chloro-N-ehtyl-N-(1-methylethyl)-1,3,5-triazine-2,4-diamine. ATZ) is a widely used agriculture herbicide that controls the growth of broadleaf and weeds. The estimated total annual usage of atrazine is ~ 76.5 million pounds in the U.S., making it the second most commonly used herbicide in the country (1) . ATZ has a relatively high water solubility (2) , and thus can be easily traced in surface and ground water by rainfalls and tile drainages(3-5).
ATZ intake from contaminated water supplies has a wide range of adverse health outcomes, including disruption of the hypothalamic-related axis in the brain by inhibiting the luteinizing hormone production and decreasing testosterone production in rats and humans and is thus known to be a potential endocrine disrupter (6) (7) (8) . Studies have also shown that ATZ exposure can demasculinize and feminize males while disrupting ovarian function in female rats (9) . Recent studies also suggest that ATZ disrupts endocrine function by altering the hypothalamic-pituitary-gonadal (HPG) axis (10) . For example, a recent work utilizing a female zebrafish animal model has found that ATZ exposure can disrupt the production of luteinizing hormone, follicle stimulating hormone and gonadotropin-releasing hormone, all of which are essential for female reproductive function (11) . In addition to its endocrine disruption functions, ATZ exposure has also been associated with several neurological disorders. Studies using a zebrafish animal model have found that ATZ exposure can introduce significant alterations to neurotransmission pathways resulting in significant decreases of serotonin metabolites in female fish (12) . Similar observations were made in mouse models, but ATZ exposure was found to primarily impact dopaminergic neurons (13) (14) (15) (16) . Interestingly, a recent epidemiological study shows that agricultural workers are at high risk of developing depression and anxiety symptoms compared to other occupational groups (17) , and the production of serotonin are associated with depression and anxiety in humans (18) . Increasing evidence indicates that ATZ-induced neurotoxicity is sex-specific, with females having a higher chance of developing non-motor symptoms (19) . Few studies, however, exist using female animal models, and the mechanisms of sex-specific neurotoxicity remain unclear.
The toxic effects of ATZ can persist after removal of exposure source and can be inherited trans-generationally (20) , suggesting the existence of underlying molecular "memory" and thus alluding to the involvement of an epigenetic mechanism. Epigenetics, including DNA methylation, histone post-translational modifications, and RNA-assisted regulation (21) , refer to reversible and inheritable changes in gene expression without altering the underlying DNA sequence. Among these, the alteration of DNA and histone methylation profiles has been the most well-studied due to its abundance and relative stability compared to other types of epigenetic modifications (22) (23) (24) . Specifically, a mouse study has found that ATZ exposure can result in deregulation of tissue-specific RNA transcription up to the third generation by inheritable decreases in H3K4me3, a transcription activation marker (25) . Similar observations were also made in a rat model (20, 26) . Our recent work has demonstrated that ATZ exposure in zebrafish can decrease global DNA methylation levels by inhibiting the activity of maintenance DNMTs and the expression level of DNMT4 and DNMT5, a zebrafish ortholog for DNMT3b (27) , but that global methylation in the adult female zebrafish brain was not changed (manuscript in review). There is, however, no genome-wide studies revealing the impact of ATZ exposure on the epigenome in the brain. In this study, we used zebrafish as an animal model and performed whole-genome bisulfite sequencing using brains harvested from 9 month-old fish that were exposed to ATZ only during embryogenesis (1-72 hour post fertilization; hpf) to reveal permanent DNA methylome changes arising from embryonic ATZ exposure. Our results suggest that genes involved in key pathways related to observed behavioral changes resulting from low-dose ATZ, such as neuroendocrine function, are differentially methylated in the brain of zebrafish exposed to ATZ. After integrating the methylation data with transcriptomic data, we suggest the ATZ-induced site-specific DNA methylation as a potential mechanism driving the aberrant expression of neurological genes.
MATERIAL AND METHODS

Zebrafish husbandry and treatment
Aliquots of a 10 parts per million (ppm; mg/L) stock solution of technical grade (98.1% purity) ATZ (CAS 1912-24-9; Chem Service, West Chester, PA) were diluted with filtered aquaria water to make exposures of 0.3, 3, and 30 ppb ATZ as previously described, with filtered aquaria water serving as the 0 ppb control (12, 28) . Embryos were collected from a breeding colony of AB wild-type zebrafish (Danio rerio) maintained in a Z-Mod System (Aquatic Habitats, Apopka, FL) with a 14:10 light-dark cycle, temperature of 26-28°C, pH 7.0-7.3, and conductivity 470-550 µS. Fish and aquaria were monitored twice daily and fed a mixture of brine shrimp (Artemia franciscana; Artemia International LLC., Fairview, Texas), Zeigler adult zebrafish food (Zeigler Bros Inc., Gardners, PA), and Golden Pearls 500-800 µm (Artemia International LLC., Fairview, Texas). To obtain embryos, adult zebrafish were bred in spawning tanks according to established protocols (29, 30) . Embryos were collected at the 4-8 cell stage, randomly sorted into the 0, 0.3, 3, or 30 ppb ATZ exposure groups, and incubated in petri dishes with 20 mL of exposure solution at 28.5°C. At 72 hpf, the larvae were rinsed in filtered aquaria water to end the ATZ exposure and then reared under normal conditions until nine months post fertilization (mpf) ( Fig. S13) (Supporting Information) . At nine mpf, the zebrafish were sexed and three randomly chosen females from each exposure were euthanized via anesthetic overdose with 0.4 mg/ml buffered tricaine-S (ethyl m-amino benzoate methanesulfonate; Western Chemical Inc., Ferndale, WA) and the brains dissected. Female zebrafish were chosen for this study due to the previously reported altered neurotransmission and gene expression changes in female zebrafish brain (12) . All protocols were approved by the Purdue University Animal Care and Use Committee and all fish treated humanely with regard to prevention and alleviation of suffering.
gDNA extraction and bisulfite conversion
gDNA was collected from nine mpf female zebrafish brain following a standard protocol modified for brain samples (27, 31) . Zebrafish brains were homogenized in lysis buffer (50 mM Tris, 100 mM EDTA, 100 mM NaCl, 1% SDS, 100 µg/mL Proteinase K) and incubated overnight at 55°C with rocking agitation. The next day, samples were transferred to 1.5
Phase Lock Gel (PLG; QuantaBio, Beverly, MA) tubes, and phenol (phenol-Tris saturated, pH 8; Roche, Indianapolis, IN) and chloroform:isoamyl alcohol (American Bioanalytical, Natick, MA) were added before the samples were centrifuged at room temperature for 5 minutes at 1500 rcf. The upper aqueous phase was transferred to a new PLG tube and the previous steps repeated. The upper aqueous phase was transferred to a 2 ml screw top microcentrifuge tube (Fisher Scientific, Hampton, NH) and 0.1X volume of 3M sodium acetate and 1X volume of isopropanol were added and the tube inverted until DNA aggregation. Samples were incubated at room temperature and then centrifuged at 4°C for 10 minutes at 800 rcf to form a DNA pellet. The pellet was washed in 70% ethanol twice, centrifuging at 4°C for 10 minutes at 800 rcf between washes. After the second wash, the pellet was centrifuged again and dried to remove remaining ethanol. The sample was rehydrated in 1xTLE buffer and incubated overnight at 55°C with rocking agitation. The following morning, the DNA quality and concentration was checked with a NanoDrop ND-1000 Spectrophotometer (Thermo Scientific, Wilmington, DE) and stored at 4°C until further analysis.
For bisulfite conversions, ~500 ng of gDNA were bisulfite-converted using EZ DNA Methylation-Gold Kit (Zymo Research, CA, USA) following the manufacturer's protocol.
Bisulfite-converted gDNA were eluted to a final concentration of ~ 100 -200 ng/μl and stored at -20°C prior to sequencing. The quality of BS-converted samples, such as fragment size, were further examined via a Picochip (Agilent Bioanalyzer, U.S.). The fragment size was found to peak at ~ 1000 nt as expected.
Bisulfite Sequencing
Next generation sequencing was performed using NovaSeq (Illumina, US) at Purdue Genomics Core Facility. All sequencing was performed at a sequencing depth of 30x coverage on the 1.5 billion base zebrafish genome. The zebrafish genome (GRCz11) was used as the reference genome.
Statistical and data analysis
All samples were collected in triplicates. The basic read quality was first verified via summaries produced by the FastQC program (Babraham Institute). Reads were then aligned to the zebrafish reference genome (GRCz11) using Bowtie 2 (32) , and the read mapping and methylation extraction was performed using Bismark v.0.21.0 (Babraham Institute) (33) . A minimum alignment score function (f(x) = 0 + -0.6x, where x is the read length) was used.
Reads aligned to identical positions on the genome were removed and bases that have more than 99.9th percentile of coverage in each sample were discarded to account for excessive PCR amplifications. In addition, reads with coverage below 10x were removed to increase the power of statistical tests.
Statistical difference in the global average CpG methylation was determined using a oneway ANOVA and F test followed by Tukey's HSD post-hoc test (n = 12). A similar test was performed using the average CpG methylation of CpG sites located within 100 bp of the TSS (n = 12). Differential methylation analysis was performed using the methylKit software package in R (34) . First, the genome was tiled with windows of 1000 bp in length and 1000 bp in stepsize. Then, a logistic regression model was fitted to predict the log-odds ratio of methylation proportion in each tile using data from all replicates. A sliding linear model (SLIM) method was used to correct P-values to q-values in order to correct for multiple hypothesis testing.
Regions with a methylation change greater than 30% and a q value less than 0.01 are considered as differentially methylated regions (DMRs). DMRs were then annotated using the Ensembl GRCz11 zebrafish build via the annotatr software package (35) .
Locations of CpG islands, introns, exons, and TSS were determined using the Ensembl GRCz11 build. For all analysis, the promoter region is considered 2000 bps upstream of the coding region due to the lack of annotated promoter sequence in zebrafish genome. Gene ontology and functional enrichment analysis was performed using the PANTHER classification system (36) . Zebrafish gene nomenclature was converted to human orthologs using Ensembl TransMap alignments in the UCSC genome browser. Subsequently, Ingenuity Pathway Analysis (IPA) was performed using human orthologs. Only experimentally-validated genes were used for pathway analysis.
Hierarchal clustering and principal component analysis were performed using R version 3.5.1. For hierarchal clustering, the Euclidean distance was used as the distance metric while McQuitty's method was used as the linkage method.
Integrated analysis of WGBS with transcriptomic data
The WGBS data was integrated with zebrafish microarray data from our previous study attained from brain tissue of adult female zebrafish aged 6 months with the same embryonic ATZ exposure (12) . Overlapping genes were determined using Ingenuity Pathway Analysis (IPA).
RESULTS
Initial alignment and quality control
Initial quality control of the sequencing data was performed using FastQC (Babraham Institute), where reads were filtered based on duplicated sequences to ensure that at least 20% of the reads were unique ( Fig. S1 ) (Supporting Information). Reads were also filtered by GC content to ensure that the distribution of GC content throughout the genome did not deviate significantly from a theoretical normal distribution ( Fig. S2 ) (Supporting Information).
Subsequently, reads were aligned to the z11 zebrafish reference genome using Bowtie 2 and Bismark. Alignment rates of reads ranged from 46.4% to 50.6% (Table S2 ) (Supporting Information). Fig. S3 (Supporting Information) illustrates the frequency of read coverage, which remains consistent between treatments.
Low dose ATZ exposure results in formation of DMRs at different chromosomal locations
We selected to work with ATZ doses of 0, 0.3, 3 and 30 ppb. The embryonic exposure of these doses is known to result in immediate transcriptomic alterations for genes associated with nervous system development (12) . The United States Environmental Protection Agency has implanted a maximum contaminant level (MCL) of 3 ppb (ppb; μ g/L) for ATZ levels in drinking water. Brain samples collected from zebrafish 9 mpf with embryonic ATZ exposure were compared here.
We first profiled the type of DNA methylation abundant in zebrafish brain. The results are shown in Fig. 1 . Throughout all samples, the vast majority of methylated cytosines were in CpG context consistent with other bisulfite sequencing data in zebrafish and mammals (37) .
CpG methylation was found to be .8074 ± .0043, .8086 ± .0027, .8071 ± .0056 and .8103 ± .0043 for 0, 0.3, 3, and 30 ppb treated zebrafish brains respectively, as shown in Table S3 (Supporting Information). There is, however, no statistically significant difference in CpG methylation percentage among treatments (p = 0.371). Fig. 2A depicts the distribution of CpG methylation throughout the genome. The proportion of CpG methylation was mainly concentrated in three distinct clusters: CpG sites with all cytosines methylated, CpG sites with ~ 75 -95% of cytosines methylated, and CpG sites with no cytosines methylated.
Different treatments exhibited similar distributions of CpG methylation with the aforementioned pattern. Fig. 2B and C illustrate the average CpG methylation per gene within exons and promoter regions respectively. In line with Fig. 2A , the genome-wide distribution of methylation was very similar among treatments both for the exon and promoter regions. Most promoter regions exhibit average methylation between 75% and 90%, and the frequency of CpG methylation at proportions below 75% is similar. In exons, an even larger proportion of genes contain methylation between 75% and 90%, and the proportion of genes with 50% methylation or less is lower than that of the promoter regions.
We then identified specific regions in the genome that exhibited significantly different levels of methylation between treatments, also known as differentially methylated regions (DMR), and grouped them based on their chromosomal locations. We categorized DMRs 
Functional Features of Identified DMRs
To better assess the sequence context and genetic location of DMRs, we annotated genes within DMRs using the GRCz11 reference genome. Genes containing at least one DMR in either the promoter or gene body are considered as a differentially methylated gene (DMG). Within approximately ~ 100 bp up-and down-stream to TSS, samples exposed to 30 ppb ATZ exhibit the highest level of methylation, with the difference most distinctive at the TSS itself (p = .0000536) (see Fig. 3C bottom). In this same range, samples exposed to 0.3 and 3 ppb ATZ exhibit similar levels of methylation, but both have higher methylation levels than untreated samples at most locations. The difference is only significant, however, between the TSS methylation levels of 30 ppb and other concentrations. Furthermore, we clustered promoter regions based on their respective CpG contexts and illustrated the methylation distribution near TSS of genes containing promoters with CpGi or CpG shore as shown in Releasing Hormone Signaling pathways, respectively for brain samples exposed to 0.3 and 30 ppb of ATZ. Equivalent results for samples exposed to 3 ppb of ATZ can be found in Fig.   S11 (Supporting Information). The number of DMGs within these selected pathways increase as ATZ concentration increases. The additional DMGs found in 30 ppb are highlighted in dotted circles in Fig. 6 .
Integrated analysis of bisulfite-seq with transcriptomic data
In order to elucidate the potential correlation of methylation patterns with gene expression resulting from ATZ exposure, we integrated data from bisulfite sequencing (this study) with gene expression data from microarray collected using zebrafish (6 mpf) with embryonic ATZ exposure (12) . We noticed the difference in our selected time-points, but the microarray data in (12) was collected from zebrafish with identical exposure to ATZ as we described in this work and thus provide a reasonable comparison point. We then focus on the four genes that were both differentially expressed and methylated in each treatment group. stickleback (Gasterosteus aculeatus) and tetraodon (Tetraodon nigroviridis) (41) . Compared to other known EDCs, i.e., BPA, the percentage of differentially methylated CpG islands was significantly higher in zebrafish exposed to ATZ. For example, the number of genes containing methylated CpG islands in zebrafish exposed to 0.3 ppb ATZ [111] was almost twice as high as that found for zebrafish exposed to 10 μ M of BPA [64] (37) .
A clustering analysis was carried out accounting for CpG methylation features of all genes ( Fig. 4) and in selected functional regions, namely promoter and exon regions ( When comparing treated to untreated control group, enzyme modulator, hydrolase, nucleic acid binding, and transcription factor proteins are found to consist the largest fraction of DMGs ( Fig. 5C-D) . Interestingly, the number of nucleic acid binding protein increases with higher doses of ATZ in hypermethylated genes, while decreasing with higher dose in Hypermethylation of opioid receptors has been associated with psychosis and AD (48, 49) .
These top affiliated pathways thus provide strong evidence that ATZ exposure can result in significant CpG pattern changes in critical neurogenic pathways which provide the molecular foundation for observed neuro-behavior changes that has been reported in ATZ exposed animal models (50) .
The wide range of biological functions and the vast number of constituent genes in the aforementioned neuronal pathways made it difficult to identify and interpret dose-dependent changes in DNA methylation of neuroendocrine and neurotransmitter signaling pathways.
Therefore, we focused on three selected pathways, namely GABA receptor signaling, longterm synaptic depression, and gonadotropin-releasing hormone signaling pathways. These pathways were selected because they were significantly enriched in all comparison groups.
They involve axonal and synaptic genes and thus can represent top pathways identified in our IPA analysis (Figs. 5E-G) . Among them, 4, 6 and 6 genes were found to consistently exhibit different CpG methylation levels in GABA receptor signaling, long-term synaptic depression and gonadotropin-releasing hormone signaling pathway, respectively, after treating with ATZ. The number of genes affected in each pathway also increase with increasing dose of ATZ.
GABA is the most abundant inhibitory neurotransmitter found in mammalian central nervous systems. GABA receptors are transmitter-gated ion channels. The amount of GABA receptor on surface can determine the strength of inhibitory synapses. Changes in GABA receptor expression is known to be regulated by DNA methylation (51) and affiliated with various psychiatric diseases, including schizophrenia-like symptoms and post-traumatic stress disorder (52, 53) . Exposure to chlorotriazine herbicide has been previously reported to cause changes in GABA A activity (54) . Interestingly, at low dose of ATZ (0.3 ppb), only GABA A receptors and GABA-gated Cl-channels are differentially methylated. At high dose of ATZ (30 pbb), GABA B , a G protein coupled receptor activated by baclofen, also becomes differentially methylated suggesting more extensive impacts on GABA receptor signaling.
GABA has also been show to interact with the hypothalamus-pituitary-gonadal (HPG) axis, as it regulates GnRH and LH release (55) .
Long-term synaptic depression accounts for an activity-dependent reduction in synaptic transmission efficiency of neurons and has been associated with motor learning (56) . In all doses of ATZ, differential methylation within synaptic receptor proteins of this pathway were observed, including IGFR-1, GRID, and AMPAR. In 30 ppb ATZ, methylation of metabotropic glutamate receptor (mGluR) and corticotropin-releasing factor (CRF) was observed. DNA methylation and other epigenetic mechanism has been implicated in modulating synaptic plasticity (57) . Abnormal methylation of identified genes have been broadly affiliated with an array of neurodegenerative and psychiatric diseases. For example, abnormal methylation in group III metabotropic glutamate receptor pathway genes have been associated with Alzheimer's Disease, Parkinson's Disease, stress and anxiety. Studies have shown that activation of mGluR7 is associated with increased levels of stress hormone corticosterone and corticotrophin which are known to trigger stress-and anxiety-like symptoms (58) , in line with observed social behavior of zebrafish following ATZ exposure (59) . Changes in locomotor activity has been previously reported in both male and female rats exposed to ATZ and attributed to disruptions in dopaminergic systems (14, 60) . Disrupted long-term synaptic depression can thus be a plausible underlying mechanism accounting for changes in locomotion of animals exposed to ATZ.
Gonadotropin-releasing hormone (GnRH) signaling pathway is a central regulator for the reproductive system and thus aligns with the suspected role of ATZ as an EDC. Alteration in this pathway can result in behavioral and phenotypic changes, such as female-specific alteration of GABA levels (see previous paragraph) and endocrinal disruption of the hypothalamus-pituitary-gonadal (HPG) axis, both of which has been previously identified in animals with atrazine exposure (6, 12) . Exposure to 0.3 ppb ATZ was observed to increase methylation levels of central protein kinases within the GnRH pathway as well as gonadotropic luteinizing hormone (LH) and CREB. LH promotes ovulation and develops the corpus luteum in females, and low-dose ATZ exposure in rats has been shown to disrupt LH pre-ovulatory surge (61) . At higher dose of ATZ (i.e., 30 ppb), in addition to the central kinase genes of the pathway, the cAMP/PKA pathway and their downstream targets CREB and CBP are also differentially methylated. CREB and ERK1/2 (also differentially methylated) are critical regulators of progesterone production, and ATZ exposure has been shown in rats to induce enhanced cAMP/PKA contributing to premature luteinization (62) .
Cancer was identified as the top affected disease in all doses by IPA, consistent with previous studies indicating the association between embryonic ATZ exposure and altered expression of genes and protein abundance in cancer-related pathways (28, 50) . TP53, a well-studied tumor suppressor gene implicated in the onset of cancer (63) , was the top predicted upstream regulator in 0.3 ppb and 3 ppb treated samples. Taken together, these results support the hypothesis that ATZ has carcinogenic effects, and present aberrant DNA methylation pattern as a plausible instigator of carcinogenesis.
Integrated methylome and gene expression analysis reveals potential methylation driven transcriptome changes after exposure to ATZ
Common genes are identified via integrated methylation and gene expression analysis as shown in Fig. 7 . Since only a few genes were found to be differentially expressed in samples treated with 3 ppb of ATZ, we focused on 0.3 and 30 ppb here. Among genes both differentially expressed and methylated, the top enriched pathways consist of a large number of neurogenic pathways such as synaptogensis signaling, opioid signaling, and calcium signaling similar as we observed in our differential methylation analysis ( Figs. 5E-F) .
Furthermore, GnRH signaling, and Long-term Synaptic Depression are enriched in common genes within both 0.3 ppb and 30 ppb, and GABA receptor signaling is enriched in common genes within 30 ppb. Taken as a whole, these results suggest DNA methylation as a driver contributing to transcriptomic aberration within neuroendocrine pathways. Dose-dependent mechanisms of methylation and gene expression within the GABA receptor warrants further study due to its role as a regulator of endocrine hormone signaling.
To further reveal the potential correlation between methylation level and gene expression, we constructed methylation-expression change plots as shown in The regulation can be partially attributed to increased methylation level in promoter regions based on our correlation analysis.
A closer look of methylation features near TSS further supports our hypothesis, as DNA methylation increases in promoter regions with increasing ATZ concentrations ( Fig. 3C and D) independent of CpG contexts. Interestingly, we also noticed a significant me CpG increase in all treatment and control groups near both ~1.3 and ~1.7 kb upstream of the TSS in genes containing CpGi, and the difference among treatments is most distinctive within this region.
This region is typically populated with super-enhancers or distal promoter elements (64) .
Increase in me CpG within these functional elements may result in decreased expression levels of genes not immediately following the sequence and can thus potentially account for other down-regulated genes found after exposure to ATZ.
A total of four common genes were identified that exhibit consistent methylation and expression level changes across all selected ATZ concentrations. All 4 genes were downregulated and exhibited a significant increase in me CpG, with the exception of CHD9 methylation in samples exposed to 0.3 ppb ATZ. Taken together with results from the previous paragraph, this observation suggest that the observed CpG methylation changes may be driving the expression changes in these genes.
We identified human orthologs of these four genes with their primarily functions listed in Fig.7E . Specifically, CHD9 gene encodes for chromodomain helicase DNA binding protein 9
belonging to a CHD family of proteins governing the access of cellular machineries to DNA.
CHD9, also known as chromatin-related mesenchymal modulator, specifically promotes the expression of osteocalcin to promote bone development (65, 66) . Altered expression of CHD9 has been observed in gastric and colorectal cancers (67) . PCLO is involved in synaptic transmission and plays a significant role in monoaminergic neurotransmission in brain. Mis-regulation of PCLO has been associated with major depressive disorders (68) .
Interestingly, depression-like neurobehavioral alterations have also been reported in ATZexposed zebrafish (69) . Fraser extracellular matrix complex subunit 1 (FRAS1), regulates epidermal-basement membrane adhesion and organogenesis during development (70) .
Mutations and abnormal expression of FRAS1 can result in Fraser Syndrome 1, and differential methylation on FRAS1 promotor region has been observed in tamoxifen resistant and fulvestrant resistant breast cancers (71) . Phosphotyrosine interaction domain containing 1 (PID1) is a retention adapter protein that regulates activity of the endocytic receptor LDL receptor-related protein 1 (LRP1). Low expression level of PID1 is observed in glioblastomas and associated with poor prognosis (72) .
Conclusions
Taken together, our results suggest that embryonic ATZ exposure can result in persistent methylation changes at specific chromosomal locations while the global methylation level and distribution remain unaffected. The number of differentially methylated regions/genes increase with higher concentrations of ATZ. ATZ treatment primarily affects methylation features of neurogenic genes associated with key pathways, such as GABA receptor signaling, long-term synaptic depression and gonadotropin-releasing hormone signaling pathways consistent with previous behavior studies using zebrafish. Integrated DNA methylation and gene expression analysis reveals that ATZ exposure primarily downregulate gene expression driven by increased DNA methylation level suggesting a potential underlying mechanism of physiological alterations following developmental ATZ exposure. In particular, the genes CHD9, FRAS1, PID1, and PLCO are promising targets for further study in their role in the developmental toxicology of ATZ due to their consistent epigenetic silencing. Furthermore, the magnitude of me CpG alteration is dependent on dose. Although small doses of ATZ were sufficient to elicit significant alterations in me CpG of neurologic pathways, exposure to higher doses of ATZ substantially increases the number of altered genes within the same pathways, suggesting more profound effects at a higher dose.
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